Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Tislelizumab With or Without Gefitinib as First-Line Treatment for HCC
NCT07829926Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Nov 2026
- Primary completion
- Nov 2026
01
Overview
A Phase 2 trial of gefitinib in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07829926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829926.